Compartir

Nacional Press Releases

29 de Marzo de 2018

Health Groups File Suit to Expedite FDA Review of E-Cigarettes, Cigars

https://nap.nationalacademies.org/resource/24952/012318ecigaretteConclusionsbyEvidence.pdfSeven public health and medical groups, and several individual pediatricians, filed suit today in federal court in Maryland challenging a U.S. Food and Drug Administration (FDA) decision that allows electronic cigarettes and cigars – including candy-flavored products that appeal to kids – to stay on the market for years without being reviewed by the agency.

23 de Marzo de 2018

Childhood Cancer Research Bill Passes Senate

The U.S. Senate passed the Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act. The bipartisan bill would advance pediatric cancer research and increase transparency and expertise for pediatric cancer research at the National Institutes of Health (NIH). 

22 de Marzo de 2018

FY 18 Budget Prioritizes Medical Research and Cancer Prevention

The U.S. House of Representatives today passed an FY 18 federal budget, which includes; a $3 billion increase for medical research at the National Institutes of Health (NIH)—the largest such funding increase in 15 years; and a $275 million increase for the National Cancer Institute (NCI). 

13 de Marzo de 2018

House Prioritizes Patient Safety; Rejects “Right-To-Try” Legislation

The House of Representatives tonight rejected legislation that would have changed the process for accessing experimental drugs without including necessary patient safeguards. The Right-to-Try legislation was opposed by the American Cancer Society Cancer Action Network (ACS CAN) along with more than 85 other organizations representing millions of patients.

12 de Marzo de 2018

Letter: Patient Safety Concerns Remain in House Right to Try Legislation

The American Cancer Society Cancer Action Network together with more than 75 organizations representing millions of patients sent a letter to leadership in the U.S. House of Representatives, expressing concerns about proposed legislation to change the process for accessing experimental drugs without including necessary patient safeguards.